Birchview Capital’s InflaRx IFRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-50,000
Closed -$67K 73
2025
Q3
$67K Hold
50,000
0.05% 67
2025
Q2
$39.5K Hold
50,000
0.04% 67
2025
Q1
$51K Hold
50,000
0.04% 65
2024
Q4
$124K Hold
50,000
0.1% 60
2024
Q3
$76.5K Hold
50,000
0.07% 55
2024
Q2
$87K Hold
50,000
0.08% 54
2024
Q1
$77K Hold
50,000
0.06% 57
2023
Q4
$81.5K Hold
50,000
0.06% 56
2023
Q3
$149K Hold
50,000
0.13% 48
2023
Q2
$223K Sell
50,000
-20,000
-29% -$89.5K 0.17% 49
2023
Q1
$136K Hold
70,000
0.11% 48
2022
Q4
$217K Hold
70,000
0.15% 48
2022
Q3
$185K Hold
70,000
0.13% 52
2022
Q2
$102K Hold
70,000
0.07% 54
2022
Q1
$128K Hold
70,000
0.09% 56
2021
Q4
$333K Hold
70,000
0.21% 54
2021
Q3
$181K Hold
70,000
0.12% 61
2021
Q2
$208K Hold
70,000
0.12% 58
2021
Q1
$273K Hold
70,000
0.16% 47
2020
Q4
$352K Hold
70,000
0.2% 45
2020
Q3
$298K Hold
70,000
0.2% 43
2020
Q2
$321K Sell
70,000
-40,000
-36% -$259K 0.19% 45
2020
Q1
$420K Buy
+110,000
New +$407K 0.37% 32
2019
Q2
Sell
-16,000
Closed -$605K 55
2019
Q1
$605K Hold
16,000
0.38% 24
2018
Q4
$582K Hold
16,000
0.55% 23
2018
Q3
$549K Hold
16,000
0.35% 30
2018
Q2
$516K Buy
+16,000
New +$553K 0.35% 31

Other funds holding IFRX

Birchview Capital's IFRX Position: Q4 2025 in Review

Birchview Capital sold out of InflaRx (IFRX) in Q4 2025, closing a stake of 50,000 shares — an estimated $67K sold.

Birchview Capital first reported a position in IFRX in Q2 2018 and held it in 27 quarters. The position peaked at $605K in Q1 2019. 34 funds tracked by Wall St. Rank hold IFRX as of Q4 2025.

  • Birchview Capital reported no remaining InflaRx position as of Q4 2025 after selling out during the quarter.
  • Birchview Capital sold 50,000 InflaRx shares in Q4 2025, an estimated $67K.
  • Birchview Capital first reported a position in InflaRx in Q2 2018 and held it in 27 quarters.
  • Birchview Capital's InflaRx position peaked at $605K in Q1 2019.
  • 34 funds tracked by Wall St. Rank held InflaRx as of Q4 2025.

Based on Birchview Capital's 13F filing for Q4 2025, filed 13 Feb 2026.